Mar 10, 2025 3:00pm EDT Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
Feb 26, 2025 7:00am EST Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
Feb 19, 2025 7:00am EST Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
Jan 10, 2025 7:00am EST Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Jan 02, 2025 7:00am EST Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
Dec 23, 2024 7:00am EST Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Dec 17, 2024 7:00am EST Immunocore announces dosing of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
Dec 11, 2024 7:00am EST EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
Dec 03, 2024 1:00am EST Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
Nov 06, 2024 7:00am EST Immunocore reports third quarter financial results and provides a business update
Sep 14, 2024 3:00am EDT Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Aug 08, 2024 7:00am EDT Immunocore reports second quarter financial results and provides a business update
Aug 01, 2024 7:00am EDT Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
Jun 18, 2024 7:00am EDT Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
Jun 01, 2024 8:00am EDT Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
May 31, 2024 4:05pm EDT Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
May 29, 2024 7:00am EDT Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
May 08, 2024 7:00am EDT Immunocore reports first quarter financial results and provides a business update
Feb 28, 2024 7:34am EST Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
Feb 22, 2024 7:00am EST Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
Feb 21, 2024 7:00am EST Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
Jan 05, 2024 7:00am EST Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
Nov 07, 2023 7:00am EST Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 01, 2023 4:01pm EDT Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
Oct 21, 2023 8:45am EDT Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
Aug 10, 2023 7:00am EDT Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
Aug 03, 2023 8:00am EDT Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
Jun 03, 2023 7:00am EDT Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
May 10, 2023 7:00am EDT Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update
May 03, 2023 4:30pm EDT Immunocore to present at the Bank of America Securities 2023 Health Care Conference
Apr 18, 2023 7:00am EDT Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival